<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03340701</url>
  </required_header>
  <id_info>
    <org_study_id>17D.559</org_study_id>
    <nct_id>NCT03340701</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Progesterone in Pregnancy</brief_title>
  <acronym>PK-PiP</acronym>
  <official_title>Pharmacokinetics of Vaginal Progesterone in Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetic analysis of 200mg vaginal progesterone suppository in women with singleton
      pregnancies between 18 0/7- 23 6/7 weeks' gestation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective study of 6 women with singleton pregnancies 18 0/7- 23 6/7 weeks' gestation with
      no prior preterm birth or short cervix who are administered a single dose of 200mg vaginal
      progesterone suppository. Serum progesterone levels will be drawn serially from pre-dose to
      24 hours post-dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 6, 2017</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Pharmacokinetic study to assess plasma concentration time profile of vaginal progesterone in pregnant women.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic model</measure>
    <time_frame>24 hours</time_frame>
    <description>Plasma concentration time profile of vaginal progesterone in pregnant women.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Progesterone</condition>
  <arm_group>
    <arm_group_label>Vaginal Progesterone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>micronized progesterone vaginal suppository 200mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vaginal progesterone suppository</intervention_name>
    <description>200mg vaginal suppository micronized progesterone</description>
    <arm_group_label>Vaginal Progesterone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years old pregnant with singleton gestation 16 0/7 - 23 6/7 weeks

          -  pre-pregnancy BMI 20-40

          -  no history of prior preterm birth

        Exclusion Criteria:

          -  history of an adverse reaction to progesterone

          -  contraindication to progesterone treatment including prior or active thrombus, active
             hepatic disease, known adverse reaction to progesterone

          -  medical comorbidity requiring medication including: hypertension, diabetes, substance
             abuse/methadone maintenance therapy, asthma, thyroid disease

          -  major fetal anomaly diagnosed on ultrasound or known chromosomal disorder

          -  multifetal gestation

          -  vaginal bleeding, preterm labor, premature rupture of membranes, or clinical
             chorioamnionitis, at the time of enrollment or on Day 1 of study

          -  any progesterone use of any form previously during the pregnancy

          -  active vaginitis

          -  Illicit substance use in pregnancy including cocaine, opiates, marijuana

          -  abnormal pap smear/+HPV on most recent pap smear

          -  known or suspected malignancy of the breast or genital organs

          -  cervical length ≤25mm
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>only women, study in pregnancy</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rupsa C Boelig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Boelig RC, Zuppa AF, Kraft WK, Caritis S. Pharmacokinetics of vaginal progesterone in pregnancy. Am J Obstet Gynecol. 2019 Sep;221(3):263.e1-263.e7. doi: 10.1016/j.ajog.2019.06.019. Epub 2019 Jun 15.</citation>
    <PMID>31211965</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>progesterone</keyword>
  <keyword>pharmacology</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

